Given that MSI-H lung cancers are extremely rare, MSI testing/MMR immunohistochemistry (IHC) is not considered as routine in lung cancer closely associated with high expression of PD-1/PD-L1 and shows durable responses to PD-1 blockade (Gregg et al., 2019). This evidence concerns the gene PDCD1 and lung cancer.